The potential economic value of a human norovirus vaccine for the United States.

TitleThe potential economic value of a human norovirus vaccine for the United States.
Publication TypeJournal Article
Year of Publication2012
AuthorsBartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY
Date Published2012 Nov 19
KeywordsAdolescent, Adult, Aged, Aged, 80 and over, Caliciviridae Infections, Child, Child, Preschool, Computer Simulation, Cost-Benefit Analysis, Female, Gastroenteritis, Humans, Infant, Infant, Newborn, Male, Middle Aged, Norovirus, United States, Viral Vaccines, Young Adult

Vaccines against human norovirus are currently under development. We developed a simulation model to determine their potential economic value. Vaccination prevented 100-6125 norovirus gastroenteritis cases per 10,000 vaccinees. Low vaccine cost (≤$50) garnered cost-savings and a more expensive vaccine led to costs per case averted comparable to other vaccines. In the US, vaccination could avert approximately 1.0-2.2 million cases (efficacy 50%, 12 month duration), costing an additional $400 million to $1.0 billion, but could save ≤$2.1 billion (48 month duration). Human norovirus vaccination can offer economic value while averting clinical outcomes, depending on price, efficacy, and protection duration.

Alternate JournalVaccine
PubMed ID23026689
PubMed Central IDPMC3517973
Grant List1U54GM088491-0109 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
Publication Categories: